Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00113321 · FLOW

Participant flow

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure · Source last updated 2012-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
    id
    FG000
    title
    Decitabine
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Study was terminated due to low accrual.
recruitment Details
Recruitment Period 3/28/05 - 11/7/08; all patients were registered at The University of Texas M.D. Anderson Cancer Center.
Complete source fields
groups
  1. description
    20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
    id
    FG000
    title
    Decitabine
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        16
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Study was terminated due to low accrual.
recruitment Details
Recruitment Period 3/28/05 - 11/7/08; all patients were registered at The University of Texas M.D. Anderson Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice